Souhaitez-vous accéder aux communiqués récents ?

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June...

NASHVILLE, TN, April 21, 2025 (GLOBE NEWSWIRE) -- Against the backdrop of Music City’s biggest weekend, leading experts and frontline clinicians will gather in downtown Nashville, Tennessee, for one...

Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and...

San Jose, CA, USA, April 08, 2025 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley skintech company, announced that its over-the-counter (OTC) Bia Eczema Relief Lotion has been awarded the Seal of...

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...

Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD).

Arcutis today announced that it will present two posters at the 2025 AAD annual meeting which will take place in Orlando, FL, from March 7-11, 2025.

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver-based biopharmaceutical company focused on skin health and healthy ageing, is pleased to...

U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025

Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old